1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
Special episode! We discuss the recent correspond…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
September 20, 201833m 41sExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
Topics
medicineoncologyhealthpolicy